Investing.com - Ascendis Pharma AS reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Ascendis Pharma AS announced earnings per share of €-2.5 on revenue of €1.02B. Analysts polled by Investing.com anticipated EPS of €-2.23 on revenue of €746.84K.
Ascendis Pharma AS shares are down 25.85% from the beginning of the year and are trading at €150.00 , down-from-52-week-high.They are under-performing the Nasdaq which is up 16.71% from the start of the year.
Ascendis Pharma AS shares gained 21.29% in after-hours trade the report.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by Pfizer on July 28, who reported EPS of €1.07 on revenue of €18.98B, compared to forecasts EPS of €0.9705 on revenue of €18.71B.
Eli Lilly had missed expectations on August 3 with second quarter EPS of €1.87 on revenue of €6.74B, compared to forecast for EPS of €1.89 on revenue of €6.6B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar